Selective MMP-12 Inhibitor Compounds for COPD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) are limited, and there is a need for effective and selective inhibitors of matrix metalloprotease MMP-12, which plays a crucial role in airway inflammation and remodeling.
Innovation Solution
Development of a compound of formula (I) and its pharmaceutically acceptable salts, which act as selective MMP-12 inhibitors, useful for treating MMP-12-mediated conditions, including COPD, through administration to inhibit MMP-12 activity and provide therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current COPD treatments are used, then existing therapeutic options are available, but treatment effectiveness is limited due to lack of selective MMP-12 inhibition
Solution Approach 1:
The patent applies local quality by designing a compound with specific functional groups positioned to interact with distinct regions of the MMP-12 active site. The hydroxamic acid moiety coordinates with the zinc ion in the catalytic site, while the aromatic substituents engage with hydrophobic pockets, creating a highly selective interaction pattern that distinguishes MMP-12 from other metalloproteases.
Solution Approach 2:
The patent employs parameter changes by systematically varying the substitution patterns on the aromatic rings, the length and branching of alkyl chains, and the position of functional groups to optimize binding affinity and selectivity. These structural parameter adjustments enable fine-tuning of the compound's interaction with MMP-12's active site geometry and electrostatic environment.
2Adaptability or versatility
If broad-spectrum MMP inhibitors are used, then multiple MMP activities are inhibited, but specificity for MMP-12 is reduced leading to off-target effects
Solution Approach 1:
The compound exhibits local quality through its specialized molecular architecture that targets MMP-12's unique active site features. The specific arrangement of the hydroxamic acid group combined with aromatic substituents creates a binding profile that exploits MMP-12's distinct structural characteristics, such as its S1' pocket geometry and zinc ion environment, thereby achieving high selectivity over other MMPs.
Solution Approach 2:
Instead of designing a broad-spectrum inhibitor that non-specifically blocks multiple MMPs, the patent inverts the approach by creating a highly selective MMP-12 inhibitor. This selective inhibition strategy avoids off-target effects on other MMPs while still achieving therapeutic benefit by specifically targeting the enzyme responsible for tissue destruction in emphysema.
3Reliability
If selective MMP-12 inhibitors are developed, then treatment specificity is improved, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a hydroxamic acid warhead for zinc coordination, an aromatic core for hydrophobic interactions, and substituent groups for fine-tuning selectivity. This modular segmentation allows systematic optimization of each component's contribution to binding affinity and selectivity while maintaining overall structural coherence.
Solution Approach 2:
The compound represents a composite molecular structure combining heterocyclic aromatic rings, alkyl chains, and hydroxamic acid functionality. This composite architecture integrates multiple chemical moieties that collectively provide both the affinity and selectivity required for specific MMP-12 inhibition, balancing structural complexity with therapeutic effectiveness.
Data Source
AI summary
Provided is a compound of formula (I):or a salt thereof, wherein R1-R5 have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and therapeutic methods comprising the administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compounds are useful as matrix metalloprotease MMP-12 inhibitors.